This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640. All subjects will receive rosiglitazone extended release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment.
The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed AVA105640. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status.
For more information on this study, visit the Study Record Detail of the respective clinical trial here.
Manuscripts citing this dataset
- Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. 2011. DOI: 2174/156720511796391935
Request access
Upon requesting access to data, you will be prompted to sign into Vivli before proceeding. Once signed in, you are ready to request data. For a detailed guide on how to request data through Vivli, check out the following How To guides here.
Data Use Agreement
The data provider requests that all Data Requestors wishing to receive access to data must execute the Data Use Agreement (DUA). Find more about the DUA here.
Publishing results using this dataset?
Vivli requires that data recipients provide Vivli with a reference citation upon publication which Vivli shall share with the applicable Data Contributor(s). Additionally, Vivli requires the recipient to acknowledge the data in a specific format. For detailed information, check out Vivli’s Data Use Agreement here.
Discuss
Post a question or thought about this dataset here.